![A liquid biopsy test has detected changes in the BRCA1 or BRCA2 genes associated with ovarian and breast cancer that signal when the disease stops responding to treatment through platinum chemotherapy or poly ADP-ribose polymerase (PARP) inhibitors. [Source: © freshidea/Fotolia]](https://www.clinicalomics.com/wp-content/uploads/2019/01/1322-218x150.jpeg "Ovarian Cancer Blood Test May Eliminate Need for Diagnostic Exploratory Surgery")
![Diagnostic firms are working to create new tests that can detect rheumatoid arthritis earlier and also provide risk assessment profiles of patients that are more or less likely to suffer permanent physical damage as a result of the disease. [©Puwadol Jaturawutthichai/Shutterstock]](https://www.clinicalomics.com/wp-content/uploads/2019/01/169-218x150.jpeg "New Targets Identified For Lupus and Rheumatoid Arthritis")
10 Countries in 100K Genome Club
These ten governments have committed funding for projects that will sequence a minimum of 100,000 citizens to spur genomic medicine
Coffee Improves Gut Motility by Altering Gut Microbiota
Data presented yesterday at the Digestive Disease Week (DDW) 2019 Conference by researchers from University of Texas, Galveston, suggest that the effects of coffee...
EMBL-EBI Launches Free Genetic Disease Diagnostic Software
Researchers at the University of Edinburgh and the European Bioinformatics Institute at the European Molecular Biology Laboratory (EMBL-EBI) have introduced a new diagnostic genome-wide...
Are Dogs the New Early Cancer Detection Tool?
A dog’s sense of smell—more than 10,000 times more sensitive than that of our own—has been exploited by humans for centuries. Whether it is...
Former Foundation Medicine Execs Join Hopkins Kimmel Directors, VCs in New Company
Steven Kafka, Ph.D., the former president and chief operating officer of Foundation Medicine who left the company last year, has joined with former colleagues...
Triple Negative Breast Cancers Activate Resistance Pathway to Evade Chemotherapy
Triple-negative breast cancers (TNBCs) are particularly aggressive, metastatic and resistant to chemotherapy treatments. Researchers at the University of Texas MD Anderson Cancer Center have...
Single Gene Deletion Halts Pancreatic Cancer in Mice
The deletion of the ataxia-telangiectasia group D-complementing (Atdc) gene, whose human homolog is up-regulated in the majority of pancreatic cancer cases, completely prevents the development of tumors in mice.
Top 600 Cancer Drug Targets Ranked Using CRISPR
Researchers from the Wellcome Sanger Institute, GlaxoSmithKline, EMBL-EBI, and Open Targets conducted one of the largest CRISPR screens of cancer genes to date.
Exclusive: A Conversation with David Bentley, VP and Chief Scientist, Illumina
From Guy's Hospital in London and the Sanger Centre during the Human Genome Project to one of the first to join early sequencing company Solexa and its subsequent acquisition by Illumina, David Bentley has seen clinical genomics come full circle.
Clinical Urologists Group Supports Genomic Testing for Prostate Cancer
AACU statement encourages use of tissue-based molecular testing and/or germline testing for three groups of prostate cancer patients
